Anika Therapeutics (ANIK) Tops Q2 EPS by 38c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.42 +1.34%
EPS Growth %: +115.4%
Financial Fact:
Net income: 0.61
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +115.4%
Financial Fact:
Net income: 0.61
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.06, $0.38 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $40.37 million.
GUIDANCE:
Anika Therapeutics sees FY2023 revenue of $159.5-163 million, versus the consensus of $161.9 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- SpaceX receives Baa1 rating from Moody's with stable outlook
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
